Form 8-K - Current report:
SEC Accession No. 0001193125-25-045628
Filing Date
2025-03-04
Accepted
2025-03-04 16:28:04
Documents
20
Period of Report
2025-03-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d878268d8k.htm   iXBRL 8-K 37947
2 EX-1.1 d878268dex11.htm EX-1.1 305047
3 EX-4.1 d878268dex41.htm EX-4.1 68679
4 EX-4.2 d878268dex42.htm EX-4.2 63301
5 EX-5.1 d878268dex51.htm EX-5.1 12220
6 EX-99.1 d878268dex991.htm EX-99.1 9812
10 GRAPHIC g878268g0304161131613.jpg GRAPHIC 3252
11 GRAPHIC g878268g0304161131854.jpg GRAPHIC 1414
  Complete submission text file 0001193125-25-045628.txt   774289

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA tnya-20250303.xsd EX-101.SCH 2883
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE tnya-20250303_lab.xml EX-101.LAB 18737
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tnya-20250303_pre.xml EX-101.PRE 11729
22 EXTRACTED XBRL INSTANCE DOCUMENT d878268d8k_htm.xml XML 3789
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

EIN.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40656 | Film No.: 25705020
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)